Aileron Therapeutics Inc. (ALRN)

Business: Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States.

IPO Date: 29-Jun-2017

Pres, CEO & Director: Dr. Manuel C. Aivado M.D., Ph.D.

Sr. VP & Chief Medical Officer: Dr. Vojislav Vukovic M.D., Ph.D.

Listing: NASDAQ: ALRN

Country: United States

Headquarters: Boston, MA

Website: https://www.aileronrx.com

Market cap: $22.10 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-27.61 Mln

Cash: $38.08 Mln

Total Debt: $0.13 Mln

Insider's Holding: 9.02%

Liquidity: Low

52 Week range: $0.23 - 1.27

Shares outstanding: 90,823,600

8 Years Aggregate:

• CFO: $-163.12 Mln
• EBITDA: $-161.02 Mln
• Net Profit: $-177.87 Mln